Does Rosuvastatin Delay Progression of Atherosclerosis in HIV

Summary

This study is a randomised double blind placebo controlled trial comparing Rosuvastatin with placebo in HIV positive people who are at intermediate cardiovascular risk. It is possible that HIV positive people will receive a greater benefit from statins because of their higher baseline levels of inflammation. Current Australian guidelines recommend initiation of statin therapy on the basis of cholesterol level and the presence of other risk factors for heart disease (such as diabetes) but do not take into account whether a patient is infected with HIV. This study aims to determine what benefit HIV infected people will receive from starting statin therapy earlier then currently recommended.

Timeline

Start

2013-07-02

Primary completion

2018-05-17

Completion

2018-11-01

Outcome

Missed primary endpoint

registry MEAN Placebo: 0.0062 (Standard Error 0.0039) mm MEAN Rosuvastatin: 0.004 (Standard Error 0.0036) mm analysis (superiority test); Placebo vs Rosuvastatin; p = 0.684 NCT01813357 ↗

Publications

• Trevillyan JM, Dart A, Paul E, Cavassini M, Fehr J, Staehelin C, Dewar EM, Hoy JF, Calmy A. Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial. AIDS. 2021 Mar 15;35(4):619-624. doi: 10.1097/QAD.0000000000002764.

Drugs

Indications